ACLARIS THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.2 USD | +0.84% |
|
-3.23% | +14.29% |
| 19/03 | Aclaris Therapeutics, Inc. Announces Board Resignations | CI |
| 27/02 | Aclaris Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Chart calendar Aclaris Therapeutics, Inc.
52b298f49eeda07b7333af90.d_0W990EExUy8TlIHlAEcFs3_Y4DuKSma7EYZ83W0LU.EaRimKhheVJUvgAEaTwpGmlPhd173_TBH_QhF66OuuocniORrXVSZAfFUg~180e6436fd1939de9f005a91e49b0017
Upcoming events on Aclaris Therapeutics, Inc.
Past events on Aclaris Therapeutics, Inc.
| 27/02/2024 05:30 pm | Q4 2023 Earnings Release |
| 13/11/2023 06:30 pm | Zunsemetinib Phase IIb Rheumatoid Arthritis Trial Results Call |
| 06/11/2023 05:30 pm | Q3 2023 Earnings Release |
| 26/09/2023 08:00 pm | Cantor Global Healthcare Conference |
| 07/08/2023 04:30 pm | Q2 2023 Earnings Release |
| 15/06/2023 05:10 am | Goldman Sachs Global Healthcare Conference |
| 09/06/2023 02:00 am | Jefferies Global Healthcare Conference |
| 01/06/2023 06:30 pm | Annual General Meeting |
| 08/05/2023 05:30 pm | Q1 2023 Earnings Call |
| 08/05/2023 04:30 pm | Q1 2023 Earnings Release |
| 30/03/2023 10:30 pm | H.C. Wainwright Autoimmune & Inflammatory Disease Conference |
| 23/02/2023 05:30 pm | FY 2022 Earnings Release |
| 14/02/2023 07:50 pm | SVB Securities Global Biopharma Conference |
| 12/01/2023 03:45 am | JP Morgan Healthcare Conference |
| 29/11/2022 08:00 pm | Piper Sandler Healthcare Conference |
| 16/11/2022 10:30 pm | Jefferies London Healthcare Conference |
| 08/11/2022 05:30 pm | Q3 2022 Earnings Release |
| 12/09/2022 04:30 pm | H.C. Wainwright Global Investment Conference |
| 03/08/2022 04:30 pm | Interim 2022 Earnings Release |
| 08/06/2022 09:00 pm | Jefferies Healthcare Conference |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 4,23 12,7 -66.79% | 6,48 6,29 2.97% | 6,76 7,05 -4.13% | 29,8 24,0 24% | 31,2 18,3 70.43% | 7,76 |
|
EBITDA Million USD | Released Forecast Spread | -86,1 -84,1 -2.37% | 0,00 0,00 - | 0,00 0,00 - | -89,1 -84,1 -5.84% | -96,5 -123 21.74% | -93,5 |
|
EBIT Million USD | Released Forecast Spread | -92,6 -120 22.96% | -50,9 -48,4 -5.08% | -89,7 -90,1 0.38% | -89,9 -91,7 2.05% | -97,4 -119 17.94% | -61,5 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -114 -129 12.29% | -51,3 -48,6 -5.7% | -90,9 -91,1 0.21% | -86,9 -91,0 4.51% | -88,8 -113 21.66% | -76,1 |
|
Net income Million USD | Released Forecast Spread | -161 -131 -23.07% | -51,0 -48,7 -4.83% | -90,9 -91,0 0.2% | -86,9 -90,5 3.94% | -88,5 -112 20.68% | -73,7 |
|
EPS USD | Released Forecast Spread | -3,90 -3,17 -22.9% | -1,20 -1,15 -4.05% | -1,60 -1,61 0.42% | -1,33 -1,46 8.98% | -1,27 -1,60 20.68% | -0,98 |
| Announcement Date | 25/02/20 | 25/02/21 | 24/02/22 | 23/02/23 | 27/02/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 1,50 1,80 -16.56% | 1,45 1,67 -12.74% | 1,53 1,61 -5.2% | 19,0 1,60 1085.34% | 7,75 1,99 288.82% | 2,53 1,75 44.6% | 1,87 1,90 -1.6% | 9,28 1,57 489.83% | 17,6 5,05 247.87% | 2,00 | 2,01 | 2,06 | 2,06 | 1,23 |
|
EBIT Million USD | Released Forecast Spread | -22,9 -23,2 1.14% | -18,9 -24,6 23.11% | -21,0 -24,5 14.23% | -20,9 -26,5 21.34% | -29,1 -29,8 2.57% | -29,9 -29,1 -2.8% | -31,8 -31,8 -0.14% | -31,6 -34,3 7.92% | -4,05 -25,2 83.92% | -14,3 | -14,2 | -13,9 | -14,5 | -35,4 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -22,8 -23,2 1.58% | -18,8 -24,6 23.56% | -20,5 -24,4 15.97% | -20,0 -26,9 25.86% | -27,6 -30,8 10.22% | -28,2 -29,0 2.75% | -29,6 -32,1 7.92% | -29,3 -34,3 14.77% | -1,86 -25,2 92.62% | -20,4 | -18,2 | -17,1 | -16,9 | -34,9 |
|
Net income Million USD | Released Forecast Spread | -22,8 -23,1 1.44% | -18,8 -24,8 24.29% | -20,5 -23,8 13.71% | -20,0 -26,3 24.16% | -27,6 -30,5 9.35% | -28,2 -29,2 3.62% | -29,6 -31,7 6.67% | -29,3 -33,9 13.81% | -1,49 -23,6 93.69% | -20,3 | -18,0 | -16,4 | -16,0 | -34,9 |
|
EPS USD | Released Forecast Spread | -0,37 -0,37 -1.37% | -0,31 -0,40 23.14% | -0,31 -0,36 13.49% | -0,30 -0,40 24.19% | -0,41 -0,46 10.14% | -0,42 -0,44 4.55% | -0,42 -0,45 7.44% | -0,41 -0,48 14.81% | -0,02 -0,33 94.01% | -0,27 | -0,24 | -0,21 | -0,21 | -0,24 |
| Announcement Date | 24/02/22 | 10/05/22 | 03/08/22 | 08/11/22 | 23/02/23 | 08/05/23 | 07/08/23 | 06/11/23 | 27/02/24 | - | - | - | - | - |
More events
Past sector events for Aclaris Therapeutics, Inc.
| 27/04/2024 | GEMPHARMATECH CO., LTD.: Q1 2024 Earnings Release |
| 27/04/2024 | GEMPHARMATECH CO., LTD.: Q4 2023 Earnings Release |
| 26/04/2024 10:30 am | BB BIOTECH AG: Q1 2024 Earnings Release |
| 26/04/2024 | BIDE PHARMATECH CO., LTD.: Q4 2023 Earnings Release |
| 26/04/2024 | PHARMARESOURCES (SHANGHAI) CO., LTD.: Q1 2024 Earnings Release |
| 26/04/2024 | HINOVA PHARMACEUTICALS INC.: Q1 2024 Earnings Release (Projected) |
| 26/04/2024 | BEIJING SUN-NOVO PHARMACEUTICAL RESEARCH CO., LTD.: Q4 2023 Earnings Release |
| 26/04/2024 | CHEMPARTNER PHARMATECH CO., LTD.: Q4 2023 Earnings Release |
| 25/04/2024 04:30 pm | MORPHIC HOLDING, INC.: Q1 2024 Earnings Release |
| 25/04/2024 11:30 am | PURETECH HEALTH PLC: Q4 2023 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- ACRS Stock
- Calendar Aclaris Therapeutics, Inc.
